Related Experiment Video
Updated: Jul 14, 2026
06:10
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants
Ian M MacDonald1, Yves Sauvé, Paul A Sieving
1National Eye Institute, National Institute of Health, Bethesda, MD 20892-1860, USA. macdonaldi@mail.nih.gov
Summary
Encapsulated cell therapy delivering ciliary neurotrophic factor shows promise for treating retinitis pigmentosa. This approach may also benefit other retinal degenerative disorders.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Cell Therapy
Background:
- Retinitis pigmentosa is a group of inherited diseases causing vision loss.
- Current treatments for retinitis pigmentosa are limited.
Purpose of the Study:
- To evaluate the safety and potential efficacy of an encapsulated cell therapy device delivering ciliary neurotrophic factor (CNTF) in patients with retinitis pigmentosa.
Main Methods:
- Phase I clinical trial.
- Implantation of an encapsulated cell therapy device designed to deliver CNTF.
- Monitoring of safety and visual function outcomes.
Main Results:
- The encapsulated cell therapy device demonstrated potential in treating retinitis pigmentosa.
- The approach was generally well-tolerated in the phase I trial.
Conclusions:
- Encapsulated cell therapy delivering CNTF is a promising approach for retinitis pigmentosa.
- Further investigation is warranted to explore its application in other retinal degenerative diseases.
